Abstract
In recent years the ability of ergot derivatives to interact with dopamine receptors has attracted considerable interest. Bromocriptine was the first ergot derivative recognised as a potent, centrally acting dopaminomimetic drug and is now widely used in the treatment of Parkinson’s disease and endocrine disorders. Ergot derivatives also proved to be valuable tools in research. For instance, the sub-classification of dopamine receptors into D-1 and D-2 types has its origin in the observation that dopaminergic ergots such as bromocriptine or lergotrile mimic the inhibitory effect of dopamine on prolactin secretion but fail to stimulate adenylate cyclase (Kebabian and Calne,1979). Recently, new types of ergot derivatives have been described which exhibit various properties of dopamine receptor antagonists and which may expand the use of these compounds into the treatment of schizophrenia. All ergot derivatives have the tetracyclic ergolene moiety as a common structural element which, in turn, bears a structural relationship to serotonin and catecholamines. It is therefore not surprising that dopaminergic ergots interact not only with dopamine but also to a certain extent, with serotonin and α-adrenoceptors. This short overview describes some novel dopaminergic ergot derivatives and their possible therapeutic uses.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Burns, R.S., Phillips, J.M., Chiueh, C.C. and Parisi, J.E. (1986). The MPTP-treated monkey model of Parkinsons disease. In MPTP: A neurotoxin producing a Parkinsonian syndrome. (eds. S.P. Markey, N. Castegnoli, A.J. Trevor, I. and J. Kopin). Academic Press, Orlando.
Closse, A., Frick, W., Dravid, A., Bolliger, G., Hauser, D., Sauter, A., Tobler, H.J. (1984). Classification of drugs according to receptor binding profiles. Naunyn Schmiedeberg’s Arch. Pharmacol. 327, 95–101
Gottfries, C.G. (1982). The metabolism of some neurotransmitters in ageing and dementia disorders. Gerontology 28 (suppl. 2), 11–19
Kebabian, J.W. and Calne, D.B. (1979). Multiple receptors for dopamine. Nature 277, 93–96
Markstein, R. (1981). Neurochemical effects of some ergot derivatives.A basis for their antiparkinson actions. J. Neural Transm. 51, 39–59
Markstein, R. (1985). Hydergine: Interaction with neurotransmitter systems in the central nervous system. J. Pharmacol (Paris) 16 (suppl.III) 1–17
Markstein, R. (1986). Pharmacological characterisation of central dopamine receptors using functional criteria. In Theneurobioloby of dopamine systems. (eds. W. Winlow, and R. Markstein) Manchester University Press, Manchester.
Markstein, R., Enz, A., Vigouret, J.M., Jaton, A., Closse, A., Briner, U., Gull, P. (1987). Biochemical, behavioural, and endocrine effects of CK 204–933, a novel 8 β-ergolene. J.Neural.Transm. 69, 179–199
Setler, P.E., Sarau, H.M., Zirkle, C.L., Saunders, H.L. (1978).The central effects of a noveldopamine agonist. European J.Pharmacol. 50, 419–430
Loew, D. and Weil. C. (1982). Hydergine in senile mental impairment. In Gerotonlogy (eds.F. Bouliere, H.P. Von Hahn and J. Andres) Karger, Basle, pp.52–74
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1988 R. Markstein, J.M. Vigouret, A. Enz, D. Coward, A. Jaton and U. Briner
About this chapter
Cite this chapter
Markstein, R., Vigouret, J.M., Enz, A., Coward, D., Jaton, A., Briner, U. (1988). Dopaminergic Ergots. In: Beart, P.M., Woodruff, G.N., Jackson, D.M. (eds) Pharmacology and Functional Regulation of Dopaminergic Neurons. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-10047-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-349-10047-7_4
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-10049-1
Online ISBN: 978-1-349-10047-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)